Eli Lilly’s Promising Position in Weight Management Market Drives Buy Rating

Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating on March 10.

David Risinger has given his Buy rating due to a combination of factors related to Eli Lilly & Co’s competitive positioning and product performance. One key factor is the promising results from Eli Lilly’s tirzepatide, which demonstrated significant weight loss in type 2 diabetic patients, comparable to Novo Nordisk’s CagriSema in similar trials. This positions Eli Lilly favorably in the weight management market, especially given the manufacturing complexities and future capacity uncertainties surrounding CagriSema.
Additionally, Eli Lilly’s ability to achieve substantial weight loss results with tirzepatide, as evidenced by the SURMOUNT-2 trial, reinforces its potential market advantage. The trial showed up to 15.5% absolute weight loss, which aligns closely with Novo Nordisk’s findings, yet with a more straightforward manufacturing process. These factors, combined with the anticipated delay in CagriSema’s regulatory filings until 2026, support the Buy rating for Eli Lilly’s stock, as the company is well-positioned to capitalize on its current market strengths.

Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Regeneron, and Vertex Pharmaceuticals. According to TipRanks, Risinger has an average return of 10.3% and a 57.49% success rate on recommended stocks.

In another report released on March 10, Morgan Stanley also reiterated a Buy rating on the stock with a $1,146.00 price target.